drugset / Trial / NCT03463551
Perfluorocarbon (ABL-101) Oxygenation for Stroke: Trial With GOLD (Glasgow Oxygen Level Dependent Technology) Imaging Theranostic
Phase 2
Unknown
18 enrolled
NHS Greater Glasgow and Clyde
Aurum Biosciences Ltd · collabUniversity of Glasgow · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This study evaluates the safety and tolerability of 3 dose levels of ABL-101 and supplemental oxygen in acute stroke patients.
Timeline
- Start
- 2018-09
- Primary completion
- 2019-09
- Completion
- 2020-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABL-101 | Diagnostic / imaging agent | 0.25 unknown | Intravenous |
| Subject | ABL-101 | Diagnostic / imaging agent | 0.5 unknown | Intravenous |
| Subject | ABL-101 | Diagnostic / imaging agent | 1.5 unknown | Intravenous |
| Subject | ABL-101 | Diagnostic / imaging agent | 3 unknown | Intravenous |